Evidence map›Paper›PMID 29134301›Full record

ArticleHistochemistry and cell biology2018

Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium.

Junyan Zhu, Doris Mayr, Christina Kuhn, Sven Mahner, Udo Jeschke, Viktoria von Schönfeldt

Abstract read
PubMed Publisher
In one paragraph

Article in Histochemistry and cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Prostaglandin E2 receptor EP1 expression in vulvar cancer.Journal of cancer research and clinical oncology · 2023
    Article
  6. Article
  7. COX-2-PGEArchives of gynecology and obstetrics · 2020
    Review
  8. Review
  9. Prostaglandin EEndocrine connections · 2018
    Article
  10. In focus in HCB.Histochemistry and cell biology · 2018
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Junyan ZhuDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Doris MayrDepartment of Pathology, LMU Munich, Thalkirchner Str. 142, 80337, Munich, Germany.
Christina KuhnDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Sven MahnerDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Udo JeschkeDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. Udo.Jeschke@med.uni-muenchen.de.ORCID http://orcid.org/0000-0003-2623-3235
Viktoria von SchönfeldtDivision of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
LMU Klinikum · DERenji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostaglandin E2 (PGE2) is well described to be associated with both endometrial functions and disorders. The primary aim of this study was to explore the underlying mechanisms that affect the growth and function of endometrial epithelium and stroma by assessing the staining intensity of PGE2 receptors (EP) in healthy endometrium across the menstrual cycle and in pathological endometrium, such as ovarian endometriosis and endometrial cancer. We retrospectively analyzed the EPs staining intensity in human nonpregnant endometrium throughout the menstrual cycle by immunohistochemistry and further focused on EP1 (n = 42). The variation of EP1 was compared among healthy endometrium, ovarian endometriosis (n = 14), and endometrial cancer (n = 140) crosswise. EP1 presented cyclical changes with increased intensity in both epithelium and stroma during the proliferative phase. EP1 staining in the epithelium was increased in endometriotic tissue compared to healthy endometrium and tumor tissue, while in the stroma, the staining in the tumor was lower than that in both normal tissue and endometriosis. No significant differences in EP1 intensity were detected for histological, stage, grading, metastatic and recurrent subtypes in endometrial cancer. EP1 was also correlated with neither progression-free survival nor overall survival of patients with cancer. EP1 staining in progesterone receptor B (PRB)-positive tumor was stronger compared to PRB-negative tumor. EP1 may play a role in human endometrial physiology and pathology. Further studies on the effect of EP1 on human endometrium are needed.

Indexed as

AdultAgedEndometrial NeoplasmsEndometriumFemaleHumansMiddle AgedReceptors, Prostaglandin E, EP1 SubtypePTGER1 protein, humanReceptors, Prostaglandin E, EP1 SubtypeEndometrial cancerEndometriosisEndometriumEP1Progesterone receptor B

Identifiers

PMID29134301
OpenAlexW2768233929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.